Xbrane Biopharma Q3 2023: Slightly higher revenues and softer EBIT - Redeye

Redeye see a Q3 report from Xbrane that came in slightly above estimates in terms of revenues, but was softer than we had forecasted on the EBIT level, the company left Q3 with SEK167.3m in cash and cash equivalents on the balance sheet.

Länk till analysen i sin helhet: https://www.redeye.se/research/964490/xbrane-biopharma-q3-2023-slightly-higher-ebit-and-softer-ebit?utm_source=finwire&utm_medium=RSS